STOCK TITAN
  1. Home
  2. News
  3. PLSE

Pulse Biosciences Inc - PLSE STOCK NEWS

Welcome to our dedicated news page for Pulse Biosciences (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulse Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulse Biosciences's position in the market.

News
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) announced it will release its first quarter 2024 financial results on May 7, 2024. The company will host a conference call for investors to discuss the results and provide insights into its CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) announced business updates and financial results for Q4 and full year 2023. Key highlights include FDA clearance for CellFX nsPFA Percutaneous Electrode, positive clinical data on benign thyroid nodules, exceptional lesion quality in cardiac catheter study, and FDA submission for Cardiac Clamp. The company plans a rights offering and universal shelf filing. Financially, GAAP costs increased driven by stock-based compensation, while non-GAAP costs rose to support product portfolio development. Cash and cash equivalents decreased to $44.4 million in Dec 2023. Full-year GAAP net loss was ($42.2) million, with non-GAAP net loss at ($33.8) million. The company will host a conference call on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
earnings
-
News
Pulse Biosciences Announces Plans to Initiate a Rights Offering
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) plans to initiate a rights offering of up to $60 million worth of units, consisting of one share of Common Stock and warrants to purchase another share. The subscription price per unit will be either $10 or the volume weighted average price of the company's stock over 10 trading days. The offering, if fully subscribed, could result in gross proceeds of $60 million with additional proceeds of up to $66 million from warrant exercises. The Company's Executive Chairman has expressed support for the offering. The rights offering will be registered with the SEC via Form S-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
none
News
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) will report financial results for Q4 and full year 2023 on March 28, 2024, showcasing its CellFX Nanosecond Pulsed Field Ablation™ technology. Investors can join the conference call or watch the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
earnings
-
News
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) receives FDA clearance for CellFX nsPFA Percutaneous Electrode System, a novel technology for soft tissue ablation in surgical procedures. The system aims to provide nonthermal removal of cellular tissue with minimal damage to noncellular structures, offering a promising treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
clinical trial
-
News
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
Rhea-AI Summary
Pulse Biosciences (PLSE) announces positive 60-day post-procedure evaluations for initial patients in the CellFX nsPFA 360° Cardiac Catheter First-In-Human Feasibility Study. The findings reveal favorable durable pulmonary vein isolation data, validating the unique nsPFA AF catheter solution. Dr. Vivek Reddy expresses optimism about the technology's potential, emphasizing ease-of-use, speed, and versatility. Pulse Biosciences aims to reshape atrial fibrillation treatment with the CellFX nsPFA 360° Cardiac Catheter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.56%
Tags
none
News
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) will feature its CellFX Nanosecond Pulsed Field (nsPFA) technology in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts. The presentation will focus on the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study and will be presented by Prof. Petr Neužil and Dr. Vivek Reddy. The technology has shown promise in the treatment of atrial fibrillation, with positive feedback from the initial procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
-
News
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) Files 510(k) Pre-market Notification for CellFX nsPFA Cardiac Clamp with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
none
-
News
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) Completes First-in-Human Feasibility Study for Atrial Fibrillation Treatment with CellFX nsPFA Cardiac Catheter
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
none
News
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
Rhea-AI Summary
Pulse Biosciences (PLSE) filed a premarket notification 510(k) to the U.S. FDA for its CellFX nsPFA percutaneous electrode, designed for non-cardiac applications. The filing was made earlier than expected, showcasing the efficiency of the FDA's new electronic submission platform. The FDA will conduct its substantive review, with a goal to complete it within 90 calendar days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
none
Stock PLSE logo
Pulse Biosciences Inc

Nasdaq:PLSE

PLSE Rankings

#3216 Ranked by Market Cap
#145 Ranked by Stock Gains
N/A Ranked by Dividends

PLSE Stock Data

398.73M
16.31M
70.38%
8.07%
4.76%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Hayward

About PLSE

pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and